Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Moderate-to-Severe Atopic Dermatitis (Ib/IIa)
CTR20201031Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Jun 2020; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20201031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201031.